Entropy Technologies LP Has $693,000 Stock Holdings in RxSight, Inc. (NASDAQ:RXST)

Entropy Technologies LP raised its holdings in shares of RxSight, Inc. (NASDAQ:RXST) by 67.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,437 shares of the company’s stock after purchasing an additional 5,399 shares during the quarter. Entropy Technologies LP’s holdings in RxSight were worth $693,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. RiverPark Advisors LLC lifted its holdings in RxSight by 70.0% during the 4th quarter. RiverPark Advisors LLC now owns 668 shares of the company’s stock valued at $27,000 after purchasing an additional 275 shares during the last quarter. Larson Financial Group LLC acquired a new stake in RxSight during the 1st quarter valued at $51,000. Amalgamated Bank lifted its holdings in RxSight by 7.7% during the 4th quarter. Amalgamated Bank now owns 4,148 shares of the company’s stock valued at $167,000 after purchasing an additional 298 shares during the last quarter. Clear Rock Advisors LLC acquired a new stake in RxSight during the 4th quarter valued at $172,000. Finally, Clarus Group Inc. acquired a new stake in RxSight during the 4th quarter valued at $202,000. Institutional investors and hedge funds own 78.78% of the company’s stock.

Insider Buying and Selling at RxSight

In other RxSight news, CEO Ronald M. Md Kurtz sold 40,000 shares of RxSight stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $60.15, for a total value of $2,406,000.00. Following the transaction, the chief executive officer now owns 764,610 shares in the company, valued at $45,991,291.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CFO Shelley B. Thunen sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $58.61, for a total value of $586,100.00. Following the completion of the transaction, the chief financial officer now owns 13,938 shares of the company’s stock, valued at $816,906.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Ronald M. Md Kurtz sold 40,000 shares of the company’s stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $60.15, for a total value of $2,406,000.00. Following the completion of the transaction, the chief executive officer now directly owns 764,610 shares of the company’s stock, valued at approximately $45,991,291.50. The disclosure for this sale can be found here. Insiders have sold a total of 75,625 shares of company stock worth $4,425,250 over the last 90 days. Insiders own 9.36% of the company’s stock.

RxSight Stock Performance

RxSight stock traded up $0.31 during midday trading on Thursday, reaching $47.53. The company’s stock had a trading volume of 37,803 shares, compared to its average volume of 460,572. RxSight, Inc. has a 52 week low of $20.66 and a 52 week high of $66.54. The business has a 50-day moving average price of $57.59 and a 200-day moving average price of $53.14.

RxSight (NASDAQ:RXST) last released its earnings results on Monday, May 6th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.08). RxSight had a negative net margin of 44.01% and a negative return on equity of 27.68%. The business had revenue of $29.51 million during the quarter, compared to the consensus estimate of $27.56 million. During the same quarter in the prior year, the firm earned ($0.42) EPS. The business’s revenue was up 68.7% on a year-over-year basis. As a group, analysts expect that RxSight, Inc. will post -0.77 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have issued reports on RXST shares. Stifel Nicolaus cut their price target on RxSight from $75.00 to $70.00 and set a “buy” rating for the company in a report on Wednesday, July 10th. Wells Fargo & Company raised their price target on RxSight from $61.00 to $68.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 7th. Oppenheimer raised their price target on RxSight from $61.00 to $72.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 7th. Needham & Company LLC raised their price target on RxSight from $64.00 to $75.00 and gave the stock a “buy” rating in a research report on Tuesday, May 7th. Finally, BTIG Research raised their price target on RxSight from $72.00 to $73.00 and gave the stock a “buy” rating in a research report on Monday. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $65.14.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.